KRAS and lung carcinoma: 10-12 Targeting KRAS had been challenging until the discovery of allosteric KRASG12C mutant-specific inhibition by covalent binding to the mutant cysteine beneath the switch-II region, which locks it in the inactive GDP bound form.13 KRASG12C inhibitors sotorasib (AMG510) and adagrasib (MRTX849) were approved by the FDA for use in lung cancer, and efficacy of these drugs in pancreatic cancer has been reported.14-17 Moreover, pan-KRAS inhibitor RMC-6236 (NCT05379985) and KRASG12D inhibitor MRTX1133 also showed promising results.18